Commercial WGS activity remains concentrated, creating a need to distinguish validated services from emerging applications
One verified clinical implementation, alongside application areas that are not yet attached to a commercial offering.
Verified commercial implementation
- Organisation
- Washington University Pathology Services (ChromoSeq)
- Application
- Clinical WGS for hematological neoplasms
- Relevant malignancy
- AML, MDS
- Clinical or RUO
- Clinical
- Commercial status
- Commercialised
- Main offering characteristics
- CAP/CLIA validated assay on blood or bone-marrow samples; approximately 60× mean coverage.
Emerging application areas
Not yet attached to a named commercial offering.
- Therapy-selection and biomarker applications
- WGS-supported MRD strategies
- Longitudinal monitoring
- Companion-diagnostic development
Where competition occurs
Clinical laboratory serviceSequencing platformBioinformatics and interpretationDiagnostic or CDx partnershipThe complete company, product, partnership and pipeline register is available with full BIS Research access.
Invivoscribe implication
Invivoscribe must differentiate against the complete clinical workflow—not only the sequencing instrument or assay.
Recommended action
Benchmark the proposed offering against verified clinical services, workflow capabilities and interpretation models.